Shineyo Medical Honored as 'Zhangjiang Pharma Valley Rising Star Enterprise 2025'
ShineyoMedical
Provider of Atrial Fibrillation Electrophysiology and Peripheral Vascular Intervention Solutions
2025·CONGRATULATION
December 6th, in the afternoon,2025 Pudong International Talent Hub Forum: Biomedical Industry Talent ForumHeld at the Zhangjiang Science Hall. The forum focused on"Talent Gathers in Pharma Valley, Wisdom Enlightens the Future"Under the guidance of the Talent Work Bureau of Pudong New Area, hosted by Shanghai Zhangjiang (Group) Co., Ltd., and co-organized by Pudong Life Science Industry Development Co., Ltd. and Waigaoqiao Biomedical Industry Development Co., Ltd.
Annual Rising Star List Released
Promising Future
Zhangjiang Medipark Rising Star Enterprise · 2025
At present, China's biopharmaceutical industry is in a critical period of innovation-driven and international development. At the forum,"Zhangjiang Medipark Annual Rising Star Enterprise · 2025"The official announcement of the list has been made. Among them,ShineyoMedicalShineyoMedical Successfully Selected and Honored with the Annual Award for Outstanding Innovation Achievements in Electrophysiology and Peripheral Interventions.
As the core area of Shanghai's biomedicine industry, Zhangjiang Pharm Valley always focuses on and cultivates enterprises with innovative vitality and technical potential. This award is a high recognition of ShineyoMedical's persistence in independent innovation and rapid development in the field of electrophysiology and peripheral intervention, and also highlights its strong momentum in product development and clinical application.
In the future, ShineyoMedical will continue to rely on the industrial ecosystem and innovative resources of Zhangjiang, deepen technological exploration, accelerate product layout, and contribute more "hardcore" strength to the industry's progress and patients' health.
2025·CONGRATULATION
About ShineyoMedical
Promising Future
【ShineyoMedical RhythPulse®-PFA System】
ShineyoMedical's RhythPulse®-PFA System is the first approved Pulse Field Ablation (PFA) system in China that integrates multi-channel, large focal, and targeted ablation, primarily used for treating rapid arrhythmias such as drug-refractory and recurrent atrial fibrillation. Its core advantages include:
Large Focal Spot Design:Using the world's first 10mm ring ablation catheter, a single discharge can cover a lesion area with a diameter of 10mm, improving the ablation efficiency by more than three times compared to traditional technology.
Targeted Ablation Technology:Equipped with an intelligent contact detection module, it monitors the contact status between the electrode and myocardial tissue in real time, reducing the risk of hemolysis caused by ineffective discharges, and decreasing postoperative plasma free hemoglobin content by 50%.
Clinical Validation Excellent:In a clinical trial involving 151 cases, the immediate success rate was 100%, and the success rate for atrial fibrillation treatment at 12 months post-operation reached 85.07%, achieving an internationally leading standard.
SHINEYOMEDICAL
WeChat ID丨ShineyoMedical
Official Website丨shineyomedical.com
-END-
